ECM
IMGN

Endurant Capital Management’s Immunogen Inc IMGN Stock Holding History

Endurant Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-86,800
Closed -$235K – 82
2019
Q1 		$235K Buy
+86,800
New +$376K 0.09% 68

Other funds holding IMGN

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Endurant Capital Management's IMGN Position: Q2 2019 in Review

Endurant Capital Management sold out of Immunogen Inc (IMGN) in Q2 2019, closing a stake of 184,440 shares — an estimated $500K sold.

Endurant Capital Management first reported a position in IMGN in Q2 2017 and held it in 6 quarters. The position peaked at $1.35M in Q4 2017. 192 funds tracked by Wall St. Rank hold IMGN as of Q2 2019.

  • Endurant Capital Management reported no remaining Immunogen Inc position as of Q2 2019 after selling out during the quarter.
  • Endurant Capital Management sold 184,440 Immunogen Inc shares in Q2 2019, an estimated $500K.
  • Endurant Capital Management first reported a position in Immunogen Inc in Q2 2017 and held it in 6 quarters.
  • Endurant Capital Management's Immunogen Inc position peaked at $1.35M in Q4 2017.
  • 192 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2019.

Based on Endurant Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.